Christopher Thomas Giordano Buys 1,612 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

Tenax Therapeutics, Inc. (NASDAQ:TENX) CEO Christopher Thomas Giordano purchased 1,612 shares of Tenax Therapeutics stock in a transaction that occurred on Tuesday, November 18th. The shares were bought at an average price of $7.75 per share, for a total transaction of $12,493.00. Following the completion of the transaction, the chief executive officer owned 1,612 shares in the company, valued at $12,493. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Christopher Thomas Giordano also recently made the following trade(s):

• On Thursday, November 20th, Christopher Thomas Giordano acquired 538 shares of Tenax Therapeutics stock. The stock was bought at an average price of $7.59 per share, with a total value of $4,083.42.
• On Wednesday, November 19th, Christopher Thomas Giordano acquired 455 shares of Tenax Therapeutics stock. The shares were bought at an average cost of $7.51 per share, with a total value of $3,417.05.

Tenax Therapeutics Stock Performance

Shares of Tenax Therapeutics stock opened at $8.15 on Friday. Tenax Therapeutics, Inc. has a 52-week low of $4.63 and a 52-week high of $8.24. The company’s 50 day moving average price is $7.14 and its 200-day moving average price is $6.36. The stock has a market capitalization of $37.19 million, a price-to-earnings ratio of -8.86 and a beta of 1.52.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Wednesday, November 12th. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.93. As a group, equities research analysts forecast that Tenax Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Wall Street Zen raised Tenax Therapeutics to a “sell” rating in a research report on Saturday, October 25th. Guggenheim reduced their price objective on shares of Tenax Therapeutics from $15.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 14th. Piper Sandler initiated coverage on shares of Tenax Therapeutics in a research report on Monday, September 8th. They issued an “overweight” rating and a $20.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenax Therapeutics in a research report on Tuesday, November 11th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. ADAR1 Capital Management LLC boosted its holdings in Tenax Therapeutics by 98.1% in the first quarter. ADAR1 Capital Management LLC now owns 68,741 shares of the specialty pharmaceutical company’s stock worth $450,000 after acquiring an additional 34,048 shares in the last quarter. Woodline Partners LP purchased a new position in shares of Tenax Therapeutics in the 3rd quarter worth about $671,000. Millennium Management LLC boosted its stake in Tenax Therapeutics by 34.2% in the 3rd quarter. Millennium Management LLC now owns 313,712 shares of the specialty pharmaceutical company’s stock worth $2,387,000 after purchasing an additional 79,998 shares in the last quarter. Citadel Advisors LLC increased its stake in Tenax Therapeutics by 318.1% during the 3rd quarter. Citadel Advisors LLC now owns 43,253 shares of the specialty pharmaceutical company’s stock valued at $329,000 after purchasing an additional 32,908 shares in the last quarter. Finally, Virtu Financial LLC purchased a new position in Tenax Therapeutics in the third quarter worth about $92,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.